CB2: Therapeutic target-in-waiting

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 38, Issue 1, 2012, Pages 16-20

  Atwood, Brady K ^a   Straiker, Alex ^b   Mackie, Ken ^b  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

Cannabinoid; Drug development; Functional selectivity; Tolerance

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; G PROTEIN COUPLED RECEPTOR; RIMONABANT; SR 144258; UNCLASSIFIED DRUG;

CLINICAL TRIAL (TOPIC); DISEASE MODEL; DRUG EFFICACY; DRUG INDICATION; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG TARGETING; HUMAN; IMMUNE DEFICIENCY; MEDICAL RESEARCH; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OSTEOPOROSIS; PAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION;

CANNABINOIDS; DRUG DISCOVERY; HUMANS; INFLAMMATION; OSTEOPOROSIS; PAIN; RECEPTOR, CANNABINOID, CB2; SIGNAL TRANSDUCTION;

EID: 84862875338     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2011.12.001     Document Type: Review

References (52)

1. 2-selective agonists. Curr Med Chem 2008, 15:1428-1443.
2. 2: a cannabinoid receptor with an identity crisis. Br J Pharmacol 2010, 160:467-479.
3. Atwood BK, Wager-Miller J, Haskins C, Straiker A, Mackie K. Functional selectivity in CB2 cannabinoid receptor signaling and regulation: implications for the therapeutic potential of CB2 ligands. Mol Pharmacol. In press.
4. Bab I., Zimmer A., Melamed E. Cannabinoids and the skeleton: from marijuana to reversal of bone loss. Ann Med 2009, 41:560-567.
5. Beltramo M. Cannabinoid type 2 receptor as a target for chronic-pain. Mini Rev Med Chem 2009, 9:11-25.
6. 2 phosphorylation by the inverse agonist SR 144528. Implications for receptor biological responses. J Biol Chem 1999, 274:20397-20405.
7. 2 cannabinoid receptor. Biochim Biophys Acta 2002, 1576:255-264.
8. Buckley N.E. The peripheral cannabinoid receptor knockout mice: an update. Br J Pharmacol 2008, 153:309-318.
9. Buckley N.E., McCoy K.L., Mezey E., Bonner T., Zimmer A., Felder C.C., et al. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur J Pharmacol 2000, 396:141-149.
10. 2 receptor-dependent mechanism. Mol Pharmacol 2004, 65:999-1007.
11. Cheng Y., Hitchcock S.A. Targeting cannabinoid agonists for inflammatory and neuropathic pain. Expert Opin Investig Drugs 2007, 16:951-965.
12. Despres J.P., Golay A., Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005, 353:2121-2134.
13. Egertova M., Elphick M.R. Localisation of cannabinoid receptors in the rat brain using antibodies to the intracellular C-terminal tail of CB. J Comp Neurol 2000, 422:159-171.
14. 2 receptors. Mol Pharmacol 1995, 48:443-450.
15. Fong T.M., Heymsfield S.B. Cannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions. Int J Obes (Lond) 2009, 33:947-955.
16. Gainetdinov R.R., Premont R.T., Bohn L.M., Lefkowitz R.J., Caron M.G. Desensitization of G protein-coupled receptors and neuronal functions. Annu Rev Neurosci 2004, 27:107-144.
17. Galiegue S., Mary S., Marchand J., Dussossoy D., Carriere D., Carayon P., et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995, 232:54-61.
18. Grimsey N.L., Goodfellow C.E., Dragunow M., Glass M. Cannabinoid receptor 2 undergoes Rab5-mediated internalization and recycles via a Rab11-dependent pathway. Biochim Biophys Acta 2011, 1813:1554-1560.
19. 2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol 2008, 153:319-334.
20. Hajos N., Katona I., Naiem S.S., MacKie K., Ledent C., Mody I., et al. Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations. Eur J Neurosci 2000, 12:3239-3249.
21. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002, 54:161-202.
22. Karsak M., Gaffal E., Date R., Wang-Eckhardt L., Rehnelt J., Petrosino S., et al. Attenuation of allergic contact dermatitis through the endocannabinoid system. Science 2007, 316:1494-1497.
23. Kurihara R., Tohyama Y., Matsusaka S., Naruse H., Kinoshita E., Tsujioka T., et al. Effects of peripheral cannabinoid receptor ligands on motility and polarization in neutrophil-like HL60 cells and human neutrophils. J Biol Chem 2006, 281:12908-12918.
24. Lazary J., Juhasz G., Hunyady L., Bagdy G. Personalized medicine can pave the way for the safe use of CB receptor antagonists. Trends Pharmacol Sci 2011, 32:270-280.
25. 2 isoforms, differential tissue expression and regulation by cannabinoid receptor ligands. Genes Brain Behav 2009, 8:519-530.
26. Luttrell L.M. Composition and function of g protein-coupled receptor signalsomes controlling mitogen-activated protein kinase activity. J Mol Neurosci 2005, 26:253-264.
27. Mailman R.B. GPCR functional selectivity has therapeutic impact. Trends Pharmacol Sci 2007, 28:390-396.
28. Mallat A., Lotersztajn S. Endocannabinoids and their role in fatty liver disease. Dig Dis 2010, 28:261-266.
29. 2) receptors plays an essential role in the protean agonism of (+)AM1241 and L768242. Br J Pharmacol 2009, 158:382-391.
30. Manera C., Tuccinardi T., Martinelli A. Indoles and related compounds as cannabinoid ligands. Mini Rev Med Chem 2008, 8:370-387.
31. 2 receptor in microglial cells in response to inflammatory stimuli. J Neurochem 2005, 95:437-445.
32. Marriott K.S., Huffman J.W. Recent advances in the development of selective ligands for the cannabinoid CB(2) receptor. Curr Top Med Chem 2008, 8:187-204.
33. Monory K., Massa F., Egertova M., Eder M., Blaudzun H., Westenbroek R., et al. The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron 2006, 51:455-466.
34. Moreira F.A., Wotjak C.T. Cannabinoids and anxiety. Curr Top Behav Neurosci 2010, 2:429-450.
35. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365:61-65.
36. Nagarkatti M., Rieder S.A., Hegde V.L., Kanada S., Nagarkatti P. Do cannabinoids have a therapeutic role in transplantation?. Trends Pharmacol Sci 2010, 31:345-350.
37. Nickerson M. Receptor occupancy and tissue response. Nature 1956, 178:697-698.
38. 2 receptor and its endogenous ligand 2-arachidonoylglycerol in 12-O-tetradecanoylphorbol-13-acetate-induced acute inflammation in mouse ear. J Biol Chem 2005, 280:18488-18497.
39. 2 cannabinoid receptors in drug abuse and depression: from mice to human subjects. PLoS One 2008, 3:e1640.
40. Patel K.D., Davison J.S., Pittman Q.J., Sharkey K.A. Cannabinoid CB(2) receptors in health and disease. Curr Med Chem 2010, 17:1393-1410.
41. Pierce K.L., Lefkowitz R.J. Classical and new roles of beta-arrestins in the regulation of G-protein-coupled receptors. Nat Rev Neurosci 2001, 2:727-733.
42. Seely K.A., Prather P.L., James L.P., Moran J.H. Marijuana-based drugs: innovative therapeutics or designer drugs of abuse?. Mol Interv 2011, 11:36-51.
43. 2 transcripts in mouse and human B lymphocytes. J Neuroimmune Pharmacol 2009, 4:476-488.
44. 2 receptors. J Pharmacol Exp Ther 2005, 315:828-838.
45. Strange P.G. Mechanisms of inverse agonism at G-protein-coupled receptors. Trends Pharmacol Sci 2002, 23:89-95.
46. Thakur G.A., Tichkule R., Bajaj S., Makriyannis A. Latest advances in cannabinoid receptor agonists. Expert Opin Ther Pat 2009, 19:1647-1673.
47. Thomas W.G. Immunoprecipitation and phosphorylation of G protein-coupled receptors. Methods Mol Biol 2009, 552:359-371.
48. 1 receptors in the rat central nervous system. Neuroscience 1998, 83:393-411.
49. Urban J.D., Clarke W.P., von Zastrow M., Nichols D.E., Kobilka B., Weinstein H., et al. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 2007, 320:1-13.
50. 2 receptor agonism protects central neurons from remote axotomy-induced apoptosis through the PI3K/Akt pathway. J Neurosci 2009, 29:4564-4570.
51. Xi Z.X., Peng X.Q., Li X., Song R., Zhang H.Y., Liu Q.R., et al. Brain cannabinoid CB receptors modulate cocaine's actions in mice. Nat Neurosci 2011, 14:1160-1166.
52. 2 receptor?. Br J Pharmacol 2006, 149:145-154.